BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260625T090000
DTEND;TZID=America/New_York:20260625T120000
DTSTAMP:20260512T082325
CREATED:20260421T152009Z
LAST-MODIFIED:20260511T162023Z
UID:3016-1782378000-1782388800@lifescievents.com
SUMMARY:Hansa Biopharma Capital Markets Day
DESCRIPTION:Join Hansa Biopharma for a Capital Markets Day featuring key opinion leaders: Matthew Cooper\, MD (Medical College of Wisconsin)\, Nassim Kamar\, MD\, PhD (Toulouse University Hospital\, France)\, Roslyn Mannon\, MD (University of Nebraska Medical Center)\, and Annette Jackson\, PhD\, F(ACHI) (Duke University Medical Center)\, and presentations by management on the Company’s pre-launch activities and pipeline strategy. \nThe program will include a review of the results from the pivotal U.S. Phase 3 ConfIdeS study presented at ATC on June 20-24\, 2026\, as well as findings from the European Post‑Authorisation Efficacy and Safety (PAES) study with Idefirix/imlifidase in Europe. Discussions with KOLs will focus on the medical need in the context of existing alternatives today for highly sensitized patients\, as well as experiences from the Phase 3 study. Company presentations will address the market opportunity and Hansa Biopharma’s pre-launch and commercialization preparations ahead of a potential U.S. approval. The day will also feature an update on Hansa’s development program for the next generation enzyme HNSA-5487 in Guillain-Barré syndrome. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/sl49bte8/.
URL:https://lifescievents.com/event/sl49bte8/
LOCATION:St. Regis Hotel\, New York\, St. Regis Hotel\, New York & Live Webcast
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Banners-3-2.png
END:VEVENT
END:VCALENDAR